DRIO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
5.3M
+2.6%
5.2M
-7.3%
5.6M
+6.7%
5.2M
+4.5%
5.0M
Cost of Revenue
2.2M
+9.1%
2.0M
-16.7%
2.4M
-1.8%
2.4M
+21.8%
2.0M
Gross Profit
3.1M
-1.5%
3.2M
-0.3%
3.2M
+14.1%
2.8M
-7.0%
3.0M
Operating Expenses
11.2M
+15.7%
9.7M
-8.0%
10.5M
-7.5%
11.4M
-9.1%
12.5M
R&D
2.3M
+9.3%
2.1M
-11.9%
2.4M
-9.5%
2.6M
-20.9%
3.3M
SG&A
8.9M
+17.5%
7.6M
-6.8%
8.1M
-7.0%
8.7M
-4.8%
9.2M
Operating Income
-8045000
-24.2%
-6479000
+11.4%
-7309000
+14.6%
-8562000
+9.7%
-9484000
EBITDA
-7521000
-26.1%
-5964000
+12.1%
-6785000
+15.5%
-8028000
+10.2%
-8938000
Net Income
-8849000
-11.7%
-7924000
+3.9%
-8249000
+8.7%
-9031000
+13.7%
-10466000
EPS (Basic)
$-0.73
+14.1%
$-0.85
-168.0%
$1.25
—
$-2.96
EPS (Diluted)
$-0.73
+14.1%
$-0.85
-168.0%
$1.25
—
$-2.96
Shares (Diluted)
12.1M
+29.1%
9.3M
-99.9%
6.6B
—
3.1M
DarioHealth (DRIO) — Financials